NASDAQ · Drug Manufacturers - Specialty & Generic

IXHL (IXHL) Stock

$2.99 +1.19% NASDAQ: IXHL Healthcare

Valuation

MetricValue
Price$2.99
Market Cap$35.71M
P/E Ratio-0.09
P/B Ratio3.28
P/S Ratio495.45
EPS (TTM)$-40.80
52-Week High$49.80
52-Week Low$2.49
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-361.54%
ROA-235.00%
ROCE-184.62%
Gross Margin100.00%
Operating Margin-379.21%
Net Margin-646.30%
Debt/Equity0.00
Current Ratio2.86

Annual Financials (USD)

Metric20212022202320242025
Revenue$1.0M$0$0$0$0
Operating Profit$-9.0M$-10.0M$-14.0M$-45.0M$-24.0M
Net Profit$-9.0M$-10.0M$-49.0M$-28.0M$-47.0M
EPS$-1.05$-1.04$-9.51$-3.42$-40.80
Op Margin-601.3%——-250341.7%-27661.6%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$7.0M$26.0M$24.0M$17.0M$20.0M
Total Liabilities$1.0M$1.0M$3.0M$6.0M$7.0M
Cash$7.0M$26.0M$22.0M$6.0M$15.0M
Borrowings$0$0$1.0M$0$0

Latest News

Incannex (IXHL) Secures U.S. Patent Grant in Obstructive Sleep Apnea for IHL-42X Insider Monkey · Jul 15, 2026 Incannex Healthcare Receives US Patent for IHL-42X in Obstructive Sleep Apnea MT Newswires · Jun 25, 2026 Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea GlobeNewswire · Jun 25, 2026 Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility GlobeNewswire · Jun 10, 2026 Incannex Announces Initiation of Research Coverage by Alliance Global Partners GlobeNewswire · Jun 9, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-5.0M$-9.0M$-11.0M$-16.0M$-13.0M
Investing Cash Flow$0$0$-1.0M$-1.0M$0
Financing Cash Flow$0$-2.0M$0$0$-25.0M
Net Cash Flow$4.0M$20.0M$-4.0M$-16.0M$9.0M
Free Cash Flow$-5.0M$-9.0M$-11.0M$-16.0M$-13.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-31.44%
Quick Ratio48.27
Interest Coverage—
Return 1Y-68.19%
Return 3Y-98.62%
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AGENAgenus Inc. $6.06 +1.34% 3.46 $252.35M 0.00%
CGTX $0.89 +0.21% -3.94 $79.79M 0.00%
IRDOpus Genetics, Inc. $3.32 +7.63% -2.35 $273.71M 0.00%
LUCD $0.97 +1.47% -1.45 $98.94M 0.00%
SCLXScilex Holding Company $6.93 +1.24% -0.18 $58.80M 0.00%

About IXHL

IXHL is led by CEO Joel Bradley Latham, employs 9 people, headquartered in AU, publicly traded since 2022.

IXHL stock trades at $2.99 with a market capitalization of $35.71M. The stock is valued at a price-to-earnings (P/E) ratio of -0.09, price-to-book of 3.28, price-to-sales of 495.45. Over the past 52 weeks the stock has ranged between $2.49 and $49.80, and currently trades 94.0% below its 52-week high.

On profitability, IXHL generates a return on equity (ROE) of -361.54%, return on capital employed of -184.62%, an operating margin of -379.21%, a net profit margin of -646.30%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides